Who is sponsoring NCT04724499?

NCT04724499 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT04724499?

Interventions in NCT04724499: High-Intensity Intervals Training, Attention Control.

What condition does NCT04724499 study?

NCT04724499 studies Breast Cancer, Chemotherapy Effect, Exercise Therapy, Cognitive Change.

Is NCT04724499 still recruiting?

NCT04724499 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT04724499: CLARITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy

Recruiting now NA Last updated 22 January 2026

What this trial tests

NA trial testing High-Intensity Intervals Training in Breast Cancer in 30 participants. Currently enrolling.

Timeline

14 July 2021

Primary endpoint
1 August 2026

1 April 2027

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	30
Start date	14 July 2021
Primary completion	1 August 2026
Estimated completion	1 April 2027
Sites	1 location across United States

Drugs / interventions tested

High-Intensity Intervals Training
Attention Control

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Chemotherapy Effect — all drugs for Chemotherapy Effect →
Exercise Therapy — all drugs for Exercise Therapy →
Cognitive Change — all drugs for Cognitive Change →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, female only, with Breast Cancer or Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to determine whether a 16-week high intensity interval training (HIIT) exercise program will improve brain health among women undergoing chemotherapy and also improve cardiovascular (heart) function. The names of the study interventions involved in this study are/is: * High-Intensity Interval Training (HIIT)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial.
Wilson R, Kang DW, Tahbaz M, Norris M, et al · · 2023 · cited 4× · PMID 37027186 · DOI 10.2196/39740
Synergy of Body Composition, Exercise Oncology, and Pharmacokinetics: A Narrative Review of Personalizing Paclitaxel Treatment for Breast Cancer.
Adriaenssens N, Wuyts SCM, Steurbaut S, De Sutter PJ, et al · · 2025 · cited 1× · PMID 40282447 · DOI 10.3390/cancers17081271

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04724499 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04724499.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing